The dollar amounts are negligible relative to market cap. Vaughn's sale was pre-planned; Caveney's was not but is still immaterial. No follow-up needed unless a larger pattern emerges.
LH drugs
LH drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 12 $372.32entry
- T+1 · 4d ago −0.49%α −0.13% · $370.48
- T+2 · todayOpen
- T+5 · in 2d Pending
- T+20 · in 24d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Two Labcorp executives sold shares totaling $852K in the past week. EVP Caveney sold $744K in an open-market sale without a 10b5-1 plan, while EVP Vaughn sold $108K under a pre-arranged plan. The combined sales represent ~0.003% of market cap, a trivial amount that does not signal a material change in outlook.
Key Financial Metrics
Key Facts
- EVP Brian Caveney sold 2,000 shares at $372.04 for $744K on Nov 10, 2026 (open-market, no 10b5-1 plan)
- EVP Bryan Vaughn sold 306 shares at $353.70 for $108K on Nov 3, 2026 (open-market, under a 10b5-1 plan)
- Total insider sales of $852K represent ~0.003% of Labcorp's $30.1B market cap
- Both sales are open-market (code S); no purchases or non-cash transactions in the cluster
Financial Impact
Total insider sales of $852K, or ~0.003% of market cap
Risk Factors
- Caveney's sale was not under a 10b5-1 plan, which could indicate personal portfolio rebalancing rather than a negative signal
- No other insiders bought shares in the window, but the sell-side signal is too small to be informative
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-LH-1794488005958 |
Track record
29 reports on LH
5 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +17.60% at T+60 after the Apr 30, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 12, 20264d ago Insider Cluster Neutral 2/10 Viewing Entry $372.32 Now $372.46 +0.04% settles Nov 19
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $372.23 Now $372.46 +0.06% settles Nov 18
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $363.30 to $372.32 Now $372.46 +2.52% ▲ +2.48% −0.81% vs SPY
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $367.79 to $372.23 Now $372.46 +1.27% ▲ +1.21% +2.12% vs SPY
- Nov 4, 202612d ago 8-K Neutral 2/10 Entry $367.79 to $372.23 Now $372.46 +1.27% ▲ +1.21% +2.12% vs SPY
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $353.92 to $370.88 Now $372.46 +5.24% ▲ +4.79% +5.38% vs SPY
- Oct 30, 202617d ago 144 Neutral 2/10 Entry $361.39 to $366.57 Now $372.46 +3.06% ▲ +1.43% +4.14% vs SPY
- Oct 28, 202619d ago 8-K Bullish 6/10 Entry $360.25 to $367.79 Now $372.46 +3.39% ▲ +2.09% +2.81% vs SPY
- Oct 26, 202621d ago Institutional Cluster Neutral 3/10 Entry $329.90 to $361.39 Now $372.46 +12.90% ▲ +9.55% +10.81% vs SPY
- Oct 21, 202626d ago 8-K Neutral 2/10 Entry $323.75 to $331.17 Now $372.46 +15.05% ▲ +2.29% +2.74% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers